• Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010).
  

PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168
Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
Clin. Cancer Res. 14:4275-4283(2008)

PubMed=20679594; DOI=10.1093/jnci/djq279
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)

PubMed=26929325; DOI=10.1073/pnas.1521812113
Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H., Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H., Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J., Hanash S.M., Ostrin E.J.
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29681454; DOI=10.1016/j.cell.2018.03.028
McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R., Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M., Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L., Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J., DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A., Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S., Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G., Posner B.A., Minna J.D., Kim H.S., White M.A.
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Cell 173:864-878.e29(2018)